ENTEREG
Total Payments
$1.2M
Transactions
1,928
Doctors
1,089
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $38,186 | 1 | 0 |
| 2021 | $214,296 | 2 | 0 |
| 2020 | $71,810 | 7 | 5 |
| 2019 | $93,597 | 294 | 200 |
| 2018 | $620,974 | 823 | 498 |
| 2017 | $207,274 | 801 | 552 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $772,923 | 12 | 62.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $311,430 | 103 | 25.0% |
| Food and Beverage | $81,354 | 1,517 | 6.5% |
| Travel and Lodging | $77,307 | 286 | 6.2% |
| Space rental or facility fees (teaching hospital only) | $2,250 | 2 | 0.2% |
| Consulting Fee | $525.00 | 1 | 0.0% |
| Education | $348.39 | 7 | 0.0% |
Payments by Type
Research
$772,923
12 transactions
General
$473,214
1,916 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-blind, Single-Center Trial of Alvimopan Entereg versus Placebo in Patients undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery after Surgery ERAS Protocol | Merck Sharp & Dohme Corporation | $404,574 | 0 |
| The ILEUS Study A Phase 2 Randomized Controlled Trial Investigating Alvimopan for Enhanced Gastrointestinal Recovery after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | Merck Sharp & Dohme Corporation | $260,864 | 0 |
| Randomized, Double-Blind, Placebo-Controlled Trial of Alvimopan in Major Spine Surgery | Merck Sharp & Dohme Corporation | $69,299 | 0 |
| A Randomized, Double-blind, Single-Center Trial of Alvimopan Entereg versus Placebo in Patients undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery after Surgery ERAS Protocol | Merck Sharp & Dohme LLC | $38,186 | 0 |
Top Doctors Receiving Payments for ENTEREG
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Stony Brook, NY | $775,173 | 14 |
| , M.D | Colon & Rectal Surgery | Houston, TX | $74,037 | 111 |
| , M.D | Colon & Rectal Surgery | Chicago, IL | $50,283 | 58 |
| , MD | Surgery | Pasadena, CA | $45,784 | 52 |
| , MD | Surgery | Philadelphia, PA | $39,918 | 40 |
| , M.D | Surgery | Saginaw, MI | $36,099 | 37 |
| , M.D | Colon & Rectal Surgery | La Jolla, CA | $30,602 | 42 |
| , MD | Colon & Rectal Surgery | Fairfield, CT | $21,886 | 22 |
| , M.D | Surgery | Indianapolis, IN | $19,872 | 29 |
| , M.D | Colon & Rectal Surgery | Atlanta, GA | $12,571 | 15 |
| , M.D, | Specialist | Bend, OR | $11,384 | 13 |
| , MD | Colon & Rectal Surgery | Miami, FL | $8,117 | 9 |
| , MD | Colon & Rectal Surgery | Mason, OH | $7,956 | 9 |
| , M.D | Colon & Rectal Surgery | Millburn, NJ | $6,205 | 7 |
| , MD | Colon & Rectal Surgery | Jacksonville, FL | $5,482 | 7 |
| , M.D | Urology | Philadelphia, PA | $4,797 | 6 |
| , MD | Urology | Los Angeles, CA | $4,273 | 6 |
| , MD | Colon & Rectal Surgery | Nashua, NH | $3,647 | 6 |
| , M.D | Anesthesiology | Stony Brook, NY | $3,537 | 3 |
| , MD | Surgery | Gurnee, IL | $3,436 | 6 |
| , MD | Surgery | Washington, DC | $2,714 | 4 |
| , M.D | Colon & Rectal Surgery | Plantation, FL | $2,633 | 3 |
| , MD | Colon & Rectal Surgery | Englewood, CO | $2,545 | 2 |
| , MD | Pediatric Gastroenterology | Columbus, OH | $525.00 | 1 |
| , M.D | Colon & Rectal Surgery | Houston, TX | $421.28 | 5 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $1.2M
- Merck Sharp & Dohme LLC $38,186
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 1,089
- Transactions 1,928
About ENTEREG
ENTEREG is a drug associated with $1.2M in payments to 1,089 healthcare providers, recorded across 1,928 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2023. In 2023, $38,186 was paid across 1 transactions to 0 doctors.
The most common payment nature for ENTEREG is "Unspecified" ($772,923, 62.0% of total).
ENTEREG is associated with 4 research studies, including "A Randomized, Double-blind, Single-Center Trial of Alvimopan Entereg versus Placebo in Patients undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery after Surgery ERAS Protocol" ($404,574).